Table 1:
Characteristics of inflammatory bowel disease (IBD) subjects and matched non-IBD comparators in the Quintiles IMS Legacy PharMetrics Adjudicated Claims Database between January 2001 and June 2016
| Non-IBD Comparators | Crohn’s Disease | Ulcerative Colitis | |
|---|---|---|---|
| N | 296,801 | 50,029 | 59,830 |
| % Female | 58 | 59 | 56 |
| Median current age in years (IQR) | 56 (46–64) | 57 (47–64) | 55 (44–63) |
| Region | |||
| % East | 24 | 24 | 24 |
| % Midwest | 30 | 31 | 30 |
| % South | 31 | 30 | 30 |
| % West | 15 | 15 | 16 |
| Charlson Comorbidity Index | |||
| % 0 | 87 | 81 | 81 |
| % 1 | 10 | 14 | 14 |
| % ≥2 | 3 | 5 | 5 |
| IBD Medication Exposure | |||
| % 5-ASA* | 0 | 24 | 37 |
| % Thiopurine | 0 | 8 | 4 |
| % Anti-TNF# | 0 | 5 | 1 |
| % Systemic Corticosteroids^ | 1 | 7 | 8 |
| Meningitis | |||
| Unique patients | 235 | 85 | 77 |
| Incidence% | 12.7 | 27.6 | 20.7 |
| Incidence Rate Ratio (95% CI) | 2.17 (1.69–2.78) | 1.63 (1.26–2.11) |
IQR: Inter-Quartile Range
*
5-Aminosalicylates: oral formulations only
#
TNF: Anti-Tumor Necrosis Factor-α
^
Defined as ≥ 2 week course of any oral systemic formulation
CI: confidence interval
%
calculated per 100,000 person-years